Pharming Group (NASDAQ:PHAR – Get Free Report) saw unusually-strong trading volume on Friday . Approximately 2,626 shares were traded during mid-day trading, a decline of 46% from the previous session’s volume of 4,869 shares.The stock last traded at $8.72 and had previously closed at $8.30.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Thursday.
View Our Latest Stock Analysis on PHAR
Pharming Group Stock Up 5.1 %
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same period last year, the firm posted $0.02 earnings per share. On average, research analysts predict that Pharming Group will post -0.15 EPS for the current year.
Institutional Trading of Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.03% of the stock is owned by hedge funds and other institutional investors.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
- Five stocks we like better than Pharming Group
- Stock Market Upgrades: What Are They?
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- There Are Different Types of Stock To Invest In
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.